Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 123

Similar articles for PubMed (Select 17825800)

1.

The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) study: outcomes from the acute and continuation phases.

Keller MB, Trivedi MH, Thase ME, Shelton RC, Kornstein SG, Nemeroff CB, Friedman ES, Gelenberg AJ, Kocsis JH, Dunner DL, Dunlop BW, Hirschfeld RM, Rothschild AJ, Ferguson JM, Schatzberg AF, Zajecka JM, Pedersen R, Yan B, Ahmed S, Schmidt M, Ninan PT.

Biol Psychiatry. 2007 Dec 15;62(12):1371-9. Epub 2007 Sep 7. Erratum in: Biol Psychiatry. 2012 Feb 15;71(4):387. Biol Psychiatry. 2008 Apr;63(7):721.

PMID:
17825800
2.

The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study: Outcomes from the 2-year and combined maintenance phases.

Keller MB, Trivedi MH, Thase ME, Shelton RC, Kornstein SG, Nemeroff CB, Friedman ES, Gelenberg AJ, Kocsis JH, Dunner DL, Hirschfeld RM, Rothschild AJ, Ferguson JM, Schatzberg AF, Zajecka JM, Pedersen RD, Yan B, Ahmed S, Musgnung J, Ninan PT.

J Clin Psychiatry. 2007 Aug;68(8):1246-56.

PMID:
17854250
3.

Influence of sex and menopausal status on response, remission, and recurrence in patients with recurrent major depressive disorder treated with venlafaxine extended release or fluoxetine: analysis of data from the PREVENT study.

Kornstein SG, Pedersen RD, Holland PJ, Nemeroff CB, Rothschild AJ, Thase ME, Trivedi MH, Ninan PT, Keller MB.

J Clin Psychiatry. 2014 Jan;75(1):62-8. doi: 10.4088/JCP.12m07841.

PMID:
24345717
4.

Comparing venlafaxine extended release and fluoxetine for preventing the recurrence of major depression: results from the PREVENT study.

Thase ME, Gelenberg A, Kornstein SG, Kocsis JH, Trivedi MH, Ninan P, Li T, Pedersen R, Keller M.

J Psychiatr Res. 2011 Mar;45(3):412-20. doi: 10.1016/j.jpsychires.2010.07.009.

PMID:
20801464
5.

Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor.

Lenox-Smith AJ, Jiang Q.

Int Clin Psychopharmacol. 2008 May;23(3):113-9. doi: 10.1097/YIC.0b013e3282f424c2.

PMID:
18408525
6.

Prevention of recurrent episodes of depression with venlafaxine ER in a 1-year maintenance phase from the PREVENT Study.

Kocsis JH, Thase ME, Trivedi MH, Shelton RC, Kornstein SG, Nemeroff CB, Friedman ES, Gelenberg AJ, Dunner DL, Hirschfeld RM, Rothschild AJ, Ferguson JM, Schatzberg AF, Zajecka JM, Pedersen RD, Yan B, Ahmed S, Musgnung J, Ninan PT, Keller MB.

J Clin Psychiatry. 2007 Jul;68(7):1014-23.

PMID:
17685736
8.

Sexual functioning in patients with recurrent major depressive disorder enrolled in the PREVENT study.

Gelenberg AJ, Dunner DL, Rothschild AJ, Pedersen R, Dorries KM, Ninan PT.

J Nerv Ment Dis. 2013 Apr;201(4):266-73. doi: 10.1097/NMD.0b013e318288d298.

PMID:
23538970
9.

A double-blind, placebo-controlled comparison of venlafaxine and fluoxetine treatment in depressed outpatients.

Nemeroff CB, Thase ME; EPIC 014 Study Group.

J Psychiatr Res. 2007 Apr-Jun;41(3-4):351-9. Epub 2005 Sep 12.

PMID:
16165158
10.

Assessing the efficacy of 2 years of maintenance treatment with venlafaxine extended release 75-225 mg/day in patients with recurrent major depression: a secondary analysis of data from the PREVENT study.

Kornstein SG, Kocsis JH, Ahmed S, Thase M, Friedman ES, Dunlop BW, Yan B, Pedersen R, Ninan PT, Li T, Keller M.

Int Clin Psychopharmacol. 2008 Nov;23(6):357-63. doi: 10.1097/YIC.0b013e328314e2cb.

12.
13.

Venlafaxine XR demonstrates higher rates of sustained remission compared to fluoxetine, paroxetine or placebo.

Shelton C, Entsuah R, Padmanabhan SK, Vinall PE.

Int Clin Psychopharmacol. 2005 Jul;20(4):233-8.

PMID:
15933485
14.
15.

A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression.

Corya SA, Williamson D, Sanger TM, Briggs SD, Case M, Tollefson G.

Depress Anxiety. 2006;23(6):364-72.

PMID:
16710853
16.

Extended-release venlafaxine in relapse prevention for patients with major depressive disorder.

Simon JS, Aguiar LM, Kunz NR, Lei D.

J Psychiatr Res. 2004 May-Jun;38(3):249-57. Erratum in: J Psychiatr Res. 42004 Jul-Aug;38(4):51.

PMID:
15003430
17.

Increased remission rates with venlafaxine compared with fluoxetine in hospitalized patients with major depression and melancholia.

Tzanakaki M, Guazzelli M, Nimatoudis I, Zissis NP, Smeraldi E, Rizzo F.

Int Clin Psychopharmacol. 2000 Jan;15(1):29-34. Erratum in: Int Clin Psychopharmacol 2000 Mar;15(2):120.

PMID:
10836283
19.

Treatment of posttraumatic stress disorder with venlafaxine extended release: a 6-month randomized controlled trial.

Davidson J, Baldwin D, Stein DJ, Kuper E, Benattia I, Ahmed S, Pedersen R, Musgnung J.

Arch Gen Psychiatry. 2006 Oct;63(10):1158-65.

PMID:
17015818
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk